迈威（上海）生物科技有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA 2024-11-14 22:00
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference 2024-11-08 22:00
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor 2024-08-26 22:00
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer 2024-08-23 22:00
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA 2024-08-12 22:00
FDA Grants Orphan Drug Designation to 7MW3711 2024-07-16 22:00
Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC 2024-07-15 22:00
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting 2024-05-24 22:00
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer 2024-05-13 22:00
FDA Grants Orphan Drug Designation to 9MW2821 2024-05-07 22:00
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor 2024-04-25 22:00
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting 2024-04-16 22:00
MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China 2024-04-08 22:00
Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London 2024-03-21 14:11
SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential 2024-03-19 22:00
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting 2024-03-12 22:00
Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London 2024-03-11 22:00
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer 2024-03-08 22:00
FDA Grants Fast Track Designation to 9MW2821 2024-02-27 22:00
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology 2024-02-21 22:00
1 2 3